Silence Therapeutics (SLN) Amortization (2019 - 2024)

Silence Therapeutics' Amortization history runs 6 years deep, the most recent figure standing at $204.7 million for Q3 2024.

• In Q3 2024, Amortization rose 84.43% year-over-year to $204.7 million; the TTM figure through Sep 2024 stood at $204.7 million (up 84.43% YoY), while the FY2023 annual figure was $100.6 million, down 15.96% from the prior year.
• Amortization came in at $204.7 million for Q3 2024 at Silence Therapeutics, down from $222.6 million in the prior quarter.
• In the past five years, Amortization ranged from a high of $230.5 million in Q1 2024 to a low of $92.5 million in Q2 2022.
• A 5-year average of $130.6 million and a median of $113.0 million in 2020 frame the typical range for Amortization.
• On a YoY basis, Amortization climbed as much as 321.87% in 2020 and fell as far as 51.78% in 2020.
• Silence Therapeutics' Amortization stood at $100.9 million in 2020, then rose by 15.36% to $116.4 million in 2021, then declined by 2.55% to $113.4 million in 2022, then declined by 11.33% to $100.6 million in 2023, then surged by 103.52% to $204.7 million in 2024.
• According to Business Quant data, Amortization over the past three periods registered $204.7 million, $222.6 million, and $230.5 million for Q3 2024, Q2 2024, and Q1 2024 respectively.

Peer Comparison